HK1255533A1 - 用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板 - Google Patents

用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板

Info

Publication number
HK1255533A1
HK1255533A1 HK18110284.4A HK18110284A HK1255533A1 HK 1255533 A1 HK1255533 A1 HK 1255533A1 HK 18110284 A HK18110284 A HK 18110284A HK 1255533 A1 HK1255533 A1 HK 1255533A1
Authority
HK
Hong Kong
Prior art keywords
colorectal cancer
protein biomarker
biomarker panels
detecting colorectal
advanced adenoma
Prior art date
Application number
HK18110284.4A
Other languages
English (en)
Inventor
John Blume
Jeffrey Jones
Ryan Benz
Athit Kao
Lisa Croner
Roslyn Dillon
Jia You
Bruce Wilcox
Original Assignee
Discerndx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discerndx Inc filed Critical Discerndx Inc
Publication of HK1255533A1 publication Critical patent/HK1255533A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Primary Health Care (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
HK18110284.4A 2015-04-10 2018-08-10 用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板 HK1255533A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562146158P 2015-04-10 2015-04-10
US201562160560P 2015-05-12 2015-05-12
US201562165846P 2015-05-22 2015-05-22
US201562196889P 2015-07-24 2015-07-24
US201562239771P 2015-10-09 2015-10-09
PCT/US2016/026773 WO2016164815A1 (en) 2015-04-10 2016-04-08 Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Publications (1)

Publication Number Publication Date
HK1255533A1 true HK1255533A1 (zh) 2019-08-16

Family

ID=55795201

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110284.4A HK1255533A1 (zh) 2015-04-10 2018-08-10 用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板

Country Status (7)

Country Link
US (3) US9689874B2 (zh)
EP (1) EP3281016A1 (zh)
JP (1) JP2018517892A (zh)
CA (1) CA2982169A1 (zh)
GB (1) GB2545361B (zh)
HK (1) HK1255533A1 (zh)
WO (1) WO2016164815A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
KR101937531B1 (ko) * 2016-09-28 2019-01-10 국립암센터 대장암 진단 장치와 대장암 진단 정보 제공 방법
US20180100858A1 (en) 2016-10-07 2018-04-12 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20200237936A1 (en) 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
US11139048B2 (en) 2017-07-18 2021-10-05 Analytics For Life Inc. Discovering novel features to use in machine learning techniques, such as machine learning techniques for diagnosing medical conditions
US11062792B2 (en) 2017-07-18 2021-07-13 Analytics For Life Inc. Discovering genomes to use in machine learning techniques
US20200386759A1 (en) * 2017-12-05 2020-12-10 Discerndx, Inc. Robust panels of colorectal cancer biomarkers
JP7102509B2 (ja) * 2018-04-04 2022-07-19 富士フイルム株式会社 医療文書作成支援装置、医療文書作成支援方法、及び医療文書作成支援プログラム
US20200011871A1 (en) * 2018-07-05 2020-01-09 Edp Biotech Corporation Kits and methods for detecting markers
US11011276B2 (en) * 2018-07-09 2021-05-18 Chang Gung Memorial Hospital, Linkou Method for establishing computer-aided data interpretation model for immune diseases by immunomarkers and visualization
JP2022550940A (ja) * 2019-10-01 2022-12-06 エーシー イミューン ソシエテ アノニム リガンドのスクリーニング用のマイクロ放射性結合アッセイ
US20210349017A1 (en) * 2020-05-08 2021-11-11 Caci, Inc. - Federal Systems and methods for detection of biological agents using infrared spectroscopy
US20240127444A1 (en) * 2021-02-16 2024-04-18 Verily Life Sciences Llc Systems and methods for biomarker detection in digitized pathology samples
EP4337910A2 (en) * 2021-05-13 2024-03-20 Arizona Board of Regents on behalf of The University of Arizona Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4517289A (en) 1982-08-18 1985-05-14 Brigham And Women's Hospital Monoclonal antibodies for human tissue cross-matching
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5790761A (en) 1992-12-11 1998-08-04 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
AU6350894A (en) 1993-03-05 1994-09-26 Clifford W. Schweinfest Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas
US7229770B1 (en) 1998-10-01 2007-06-12 The Regents Of The University Of California YKL-40 as a marker and prognostic indicator for cancers
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US5800347A (en) 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
NO954667D0 (no) 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
US5983211A (en) 1996-01-24 1999-11-09 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
US6242212B1 (en) 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6303372B1 (en) 1998-06-12 2001-10-16 Chiron Corporation cDNA molecule encoding human CIF130
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
AU767833B2 (en) 1999-01-10 2003-11-27 Exact Sciences Corporation Methods of detecting colorectal disease
US7153700B1 (en) 1999-03-26 2006-12-26 Dana-Farber Cancer Institute, Inc. Methods and compositions for diagnosing and predicting the behavior of cancer
ES2244417T3 (es) 1999-04-09 2005-12-16 Rigshospitalet Inhibidor de tejido de metaloproteasa de matriz tipo-1 (timp-1) como un marcador de cancer.
US20010041365A1 (en) 2000-01-10 2001-11-15 Michael Laposata Methods for monitoring alcohol consumption
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US7301016B2 (en) 2000-03-07 2007-11-27 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
US7577683B2 (en) 2000-06-08 2009-08-18 Ingenuity Systems, Inc. Methods for the construction and maintenance of a knowledge representation system
US6531283B1 (en) 2000-06-20 2003-03-11 Molecular Staging, Inc. Protein expression profiling
DE60142356D1 (de) 2000-07-18 2010-07-22 Millennium Pharm Inc 18480 humane proteinkinasemoleküle und ihre verwendungen
US6706506B2 (en) 2000-07-24 2004-03-16 Cornell Research Foundation, Inc. Detection of epithelial cell cancers and precancerous conditions
AU2001297575A1 (en) 2000-11-08 2002-10-08 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
US7312086B2 (en) 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
EP1430145B1 (en) 2001-03-23 2013-01-02 Yeda Research And Development Co., Ltd. Methods for determing a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a dna repair enzyme and a cancer
BR0209646A (pt) 2001-05-16 2006-10-10 Novartis Ag genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
US7031846B2 (en) 2001-08-16 2006-04-18 Affymetrix, Inc. Method, system, and computer software for the presentation and storage of analysis results
EP1430071B1 (en) 2001-09-07 2011-04-06 The Johns Hopkins University School Of Medicine Secreted and cell surface genes expressed in benign and malignant colorectal tumors
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
US20030186248A1 (en) 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
AU2003268905A1 (en) 2002-05-21 2003-12-02 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
US20050153382A1 (en) 2002-06-06 2005-07-14 Chengdu Kuachang Science And Technology Co., Ltd. Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
DE102004037860A1 (de) 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
WO2006015616A1 (en) 2004-08-13 2006-02-16 Indivumed Gmbh Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
WO2006047482A2 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Method for determining the diagnosis, malignant potential, and biologic behavior of pancreatic cysts using cyst aspirate
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
WO2006094149A2 (en) 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
US9075062B2 (en) 2005-03-22 2015-07-07 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Identification of biomarkers by serum protein profiling
ES2717627T3 (es) 2005-07-29 2019-06-24 Siemens Healthcare Diagnostics Inc Métodos, kits, sistemas y bases de datos relacionados con enfermedades neoplásicas
SG182169A1 (en) 2005-09-12 2012-07-30 Phenomenome Discoveries Inc Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites
CN101263391A (zh) 2005-09-12 2008-09-10 菲诺梅诺米发现公司 通过测量维生素e-相关的代谢物诊断结肠直肠癌和卵巢癌的方法
EP1937831B1 (en) 2005-09-27 2012-08-01 University of Saskatchewan Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis
EP1946118A4 (en) 2005-11-10 2009-01-21 Aurelium Biopharma Inc TISSUE DIAGNOSIS OF BREAST CANCER
GB0524190D0 (en) 2005-11-28 2006-01-04 Helse Stavanger Hf Method
ES2277785B1 (es) 2005-12-21 2008-06-16 Oryzon Genomics, S.A. Metodo de analisis de expresion diferencial en cancer colorectal.
US20090035801A1 (en) 2005-12-27 2009-02-05 Power3 Medical Products, Inc. Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
EP2412822A1 (en) 2006-01-11 2012-02-01 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
WO2007090125A2 (en) 2006-01-30 2007-08-09 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
WO2007127002A2 (en) 2006-03-31 2007-11-08 Cell Signaling Technology, Inc. Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors
WO2007149456A2 (en) 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
WO2008073858A2 (en) 2006-12-08 2008-06-19 The Johns Hopkins University Cancer chemoprevention strategy based on loss of imprinting of igf2
BRPI0806437A2 (pt) 2007-01-26 2011-09-06 Univ Lousville Res Foundation Inc métodos de detecção de auto-anticorpos para diagnóstico e caracterização de distúrbio
WO2008116178A2 (en) 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
CA2688558A1 (en) 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
DE102007034993A1 (de) 2007-07-26 2009-01-29 Hanna Diehl Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs
WO2009015299A1 (en) 2007-07-26 2009-01-29 California Pacific Medical Center Method to predict or diagnose a gastrointestinal disorder or disease
WO2009040782A2 (en) 2007-09-28 2009-04-02 Royal College Of Surgeons In Ireland A method of assessing colorectal cancer status in an individual
ATE521894T1 (de) 2007-11-20 2011-09-15 Hoffmann La Roche Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
KR101058753B1 (ko) 2007-11-22 2011-08-24 한국생명공학연구원 대장암 마커로서의 ｅｓｍ－１ 유전자 및 이를 이용한대장암의 진단 및 치료에의 용도
BRPI0820793A2 (pt) 2007-12-10 2015-06-16 Hoffmann La Roche Seprase como marcador de câncer
JP5591711B2 (ja) * 2007-12-10 2014-09-17 エフ．ホフマン−ラ ロシュ アーゲー 結腸直腸癌のためのマーカーパネル
US20110052581A1 (en) 2008-02-08 2011-03-03 Poniard Pharmaceuticals Inc. Use of picoplatin and cetuximab to treat colorectal cancer
CN102027128A (zh) 2008-02-11 2011-04-20 哈达斯特医学服务与开发有限公司 作为癌症标志物的结肠癌相关的转录物1(ccat-1)
JPWO2009107170A1 (ja) 2008-02-29 2011-06-30 学校法人日本大学 抗ｃｒｐ抗体及びその利用
EP2255017A1 (en) 2008-03-18 2010-12-01 Epigenomics AG A method for optimizing and validating an assay for determining the presence or absence of a medical condition
JP2011515478A (ja) 2008-03-25 2011-05-19 シェーリング コーポレイション 結腸直腸がんを処置または予防するための方法
US8921074B2 (en) 2008-04-10 2014-12-30 Genenews, Inc. Method and apparatus for determining a probability of colorectal cancer in a subject
WO2009138392A1 (en) 2008-05-14 2009-11-19 ETH Zürich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
EP2796878A1 (en) 2008-05-23 2014-10-29 Biocartis NV New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof
CA2731216A1 (en) 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
EP2169077A1 (en) 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
US20100204299A1 (en) 2009-02-11 2010-08-12 Daniel Regnier C-cbl and antagonists thereof for the treatment and diagnosis of cancer
JP2012517607A (ja) 2009-02-20 2012-08-02 オンコノム，インコーポレイテッド 大腸癌の診断及び予後判定のための用具セット及び方法
JP5384672B2 (ja) 2009-02-24 2014-01-08 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｓ−ＥｒｂＢ−３の使用
KR20120105444A (ko) 2009-10-15 2012-09-25 오클라호마 메디컬 리써치 화운데이션 염증성 질병의 활성 측정 및 모니터링을 위한 바이오마커 및 방법
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
CA2781408A1 (en) * 2009-11-20 2011-05-26 University Of Louisville Research Foundation Inc. Biomarkers of cancer
ES2633111T3 (es) 2010-03-26 2017-09-19 Hongzhi Zou Métodos y materiales para detectar neoplasia colorrectal
US10119959B2 (en) 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
GB201012590D0 (en) 2010-07-27 2010-09-08 Queen Mary & Westfield College Methods for diagnosing cancer
US8389684B2 (en) 2010-09-13 2013-03-05 Tsinghua University Tumor biomarker
ES2545515T3 (es) 2011-01-28 2015-09-11 F. Hoffmann-La Roche Ag Biomarcadores combinatorios para aplicaciones clínicas en la gestión del paciente con cáncer de pulmón
US20140141986A1 (en) 2011-02-22 2014-05-22 David Spetzler Circulating biomarkers
EP2744919A4 (en) 2011-08-19 2015-04-08 Myriad Genetics Inc GENE SIGNATURES FOR PROGNOSIS OF LUNG CANCER AND SELECTION OF THERAPY
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US20150141273A1 (en) * 2012-04-26 2015-05-21 Stichting Vu-Vumc Biomarkers
CA2893158A1 (en) 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors

Also Published As

Publication number Publication date
US20170370937A1 (en) 2017-12-28
GB2545361B (en) 2018-01-24
GB2545361A (en) 2017-06-14
WO2016164815A1 (en) 2016-10-13
US20160299144A1 (en) 2016-10-13
GB201703773D0 (en) 2017-04-26
US20190257835A1 (en) 2019-08-22
JP2018517892A (ja) 2018-07-05
CA2982169A1 (en) 2016-10-13
US9689874B2 (en) 2017-06-27
EP3281016A1 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
HK1255533A1 (zh) 用於檢測大腸癌及進階性腺瘤的蛋白質生物標誌物面板
IL276481B (en) Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer
HK1248285A1 (zh) 判定癌症狀態之方法及系統
HK1246828A1 (zh) 用於檢測癌症的生物標志物組
HK1217219A1 (zh) 結直腸癌生物標誌物
IL247987A0 (en) Protein biomarker profiles for colon tumor detection
GB201808422D0 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
IL253710A0 (en) Biomarkers for pancreatic cancer, and kits and methods to detect them
EP3647788A4 (en) BIOMARKER FOR THE DETECTION OF COLORECTAL CANCER
IL267315A (en) Methods of determining colorectal cancer status in an individual
SG11201701875YA (en) Methods for detecting ovarian cancer
IL264359A (en) Combined test for colon cancer
EP3134545A4 (en) Method and biomarker for detecting cancer
EP2972376A4 (en) Methods for determining prognosis of colorectal cancer
HK1249134A1 (zh) 結直腸癌相關疾病的生物標誌物
IL257514A (en) A method for detecting cancer
EP3258923A4 (en) METHODS AND SUBSTANCES FOR EVALUATING RESPONSE TO CHEMOTHERAPY AND TREATING CANCER
PL3545109T3 (pl) Sposób identyfikacji in vitro gruczolaków jelita grubego lub raka jelita grubego
GB201411393D0 (en) Agents and methods for determining colorectal cancer status
GB201604809D0 (en) Method for detecting cancer
GB201604813D0 (en) Methods for detecting cancer
GB201508185D0 (en) Methods of detecting and predicting cancer
AU2015903361A0 (en) Cancer detection method